A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks

10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks

25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks

50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks

The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.